Humbi AI by Innovaccer and Landmark Science to Present Real-World Evidence on GLP-1 Use for Cardiometabolic and Cardiovascular Risk Reduction in Medicare Populations at ISPOR 2025
Article content
Article content
MONTREAL — Innovaccer, the leading healthcare AI company, today announced that its recently acquired actuarial science company – Humbi AI, in collaboration with Landmark Science, Inc., will present a joint research at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 annual conference, scheduled to take place between May 13–16 in Montreal, QC, Canada.
Article content
The research offers new insights into the characteristics of Medicare patients initiating GLP-1 receptor agonists (RAs) and Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction.
Article content
The research, leveraging Humbi AI's high-quality real-world Medicare dataset, provides a timely look into patient populations initiating these therapies—an area of growing importance as GLP-1 RAs expand beyond diabetes management.
Article content
'The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity,' said Puneet Budhiraja – Vice President, Analytics at Humbi AI by Innovaccer. 'At ISPOR, we're excited to share data that helps stakeholders better understand who is initiating these therapies – and who might be left behind.'
Article content
'The importance of real-world evidence in understanding semaglutide's impact on cardiovascular disease among Medicare patients cannot be overstated, particularly given the risk of heart attack and stroke among this older population,' said Shivani Aggarwal – CEO of Landmark Science.
Article content
The two joint poster presentations by HumbiAI and Landmark Science, Inc. include:
Article content
Poster #EPH74 (Poster Session 2, 14th May, 4:00PM – 7:00PM):
Characteristics of Patients Initiating Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments.
View Poster Abstract
Article content
Humbi AI by Innovaccer is an actuarial intelligence company powered by Medicare, Medicaid, and Commercial datasets enabling providers, payers, and life sciences organizations to manage risk, improve performance, and succeed in value-based care. With deep actuarial expertise, robust benchmarking data, and flexible financial modeling software, Humbi AI provides powerful analytics and consultative services that transform complex challenges into actionable insights. By simplifying risk management and enhancing decision-making, Humbi AI by Innovaccer helps organizations drive better outcomes and sustainable growth. For more information, visit humbi.ai.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
13 hours ago
- Vancouver Sun
Health Canada approves Ozempic for kidney protection in Type 2 diabetics
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. 'What my patients are scared of is dialysis — dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. In an email, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues — the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
Globe and Mail
15 hours ago
- Globe and Mail
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in pre-market on Aug. 19, 2025. FDA Gives Green Signal to Wegovy for MASH On Friday, the company announced that Wegovy had been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. The treatment is to be used in combination with a reduced-calorie diet and increased physical activity. First GLP-1 Therapy Approved for MASH The approval makes Wegovy the first GLP-1 class treatment authorized for MASH, a progressive liver condition estimated to affect around 5% of U.S. adults, according to the American Liver Foundation, as quoted on CNBC. This achievement expands Wegovy's use beyond diabetes and obesity, strengthening Novo Nordisk's position in the metabolic disease market. Previous studies have also shown the drug's effectiveness in lowering the risks of heart attack, stroke and cardiovascular-related death. Results From the ESSENCE Trial The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy's superior efficacy over placebo in improving liver fibrosis. Notably, 62.9% of participants on Wegovy achieved the resolution of steatohepatitis with no worsening of fibrosis compared to 34.3% on placebo. About 36.8% achieved improvement in liver fibrosis without worsening steatohepatitis after 72 weeks versus 22.4% on placebo. The second phase of the trial is expected to conclude in 2029. Market Impact Novo Nordisk confirmed that Wegovy would be immediately available in the United States for MASH treatment. Currently, the only other FDA-approved therapy for MASH is Madrigal Pharmaceuticals' Rezdiffra, which received clearance in 2024. This means Novo Nordisk's Wegovy should make a killing from businesses generated from MASH treatment. NVO-Heavy ETFs in Focus Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) that are heavy on Novo Nordisk. The NVO has solid exposure to ETFs like Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and VanEck Pharmaceutical ETF PPH. Boost Your Portfolio with Our Top ETF Insights Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week. Don't miss out on this valuable resource. It's free! Get it now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report VanEck Pharmaceutical ETF (PPH): ETF Research Reports Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports This article originally published on Zacks Investment Research (
Global News
15 hours ago
- Global News
Ozempic approved in Canada to reduce kidney decline in people with diabetes
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. Story continues below advertisement 'What my patients are scared of is dialysis — dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 2:07 Ozempic can help prevent limb loss in some patients living with peripheral artery disease, trial shows 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Story continues below advertisement Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy In an email, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. Story continues below advertisement 1:54 GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer's risk for those with diabetes The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. Story continues below advertisement 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues — the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes.
